Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PTCT
PTC THERAPEUTICS, INC.
NASDAQ
$70.09
▼ DOWN 2.40% (-1.72)

KEY STATISTICS

Market Cap$5.85 B
52w High$90.87
52w Low$49.38
Dividend Yield—
Frequency—
P/E-30.08
Volume691.05K
Shares Out.83.46M

COMPANY

LEADERSHIP

Matthew Klein
CHIEF EXECUTIVE
Matthew Klein

COMPENSATION 2026

Salary$958,500
Stock Awards$16,593,800
Incentive Plan Pay$1,294,000
All Other Comp.$20,266
Total$23,266,326

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 20, 2013
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
991

PRICE TARGET

Target High$130.00
Target Low$85.00
Target Median$108.00
Target Consensus$106.14

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$302.31M
NOV
3
TUE

PRICE

$70.09 ▼ DOWN 2.40% (−$1.72)
$69.50$70.00$70.50$71.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM70.09

About PTC Therapeutics, Inc.

https://www.ptcbio.com ↗

PTC Therapeutics, Inc. is a biopharma company developing and commercializing medicines for rare diseases, including Duchenne muscular dystrophy and spinal muscular atrophy, with a diverse pipeline and global collaborations.

INDUSTRY

Biotechnology

A PRODUCT PTC THERAPEUTICS, INC. IS KNOWN FOR

Sephience™ (sepiapterin)
Sephience™ (sepiapterin)

Sephience is an oral therapy for PKU, launched in late 2025, gaining strong global adoption and serving as a key driver of the company's future revenue growth.

COMPETITORS

COMPETITOR
BMRN COMPARE
CDXS COMPARE
RARE COMPARE
SRPT COMPARE
SYBX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$130.96M $183.99M ▲$225.57M ▲$238.82M ▲
Royalty$70.79M $79.39M ▲$46.84M ▼$71.11M ▲
Collaboration and License Revenue$9.26M $0 ▼$143K ▲$50.59M ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$56.42M $159.41M ▲$136.52M ▼$152.18M ▲
NonUS$74.53M $178.01M ▲$89.06M ▼$86.64M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
231
LISTED HERE
26
RANKED BY POSITION SIZE
XSMC.TO
0.34% · 5.1M
VTI
0.01% · 2.6M
XBI
0.87% · 1.4M
XSMO
1.54% · 650.3K
SCHA
0.12% · 393.6K
DFAS
0.10% · 223.6K
FESM
0.23% · 210.1K
FTXH
1.11% · 164.4K
JSMD
0.98% · 146.3K
ABFL
0.75% · 75.8K
XRSU.L
0.18% · 74.8K
LABU
0.59% · 52.5K
EZM
0.31% · 40.9K
RSSL
0.19% · 39.6K
GSSC
0.23% · 35.6K
BR
BRNY
0.39% · 34.1K
FSCC
0.60% · 28.7K
ROUS
0.26% · 26.9K
TQSM.TO
0.25% · 26.8K
JHSC
0.25% · 25.2K
SIXS
1.17% · 23.6K
BBSC
0.20% · 20.9K
BBP
1.17% · 19.5K
TPSC
0.18% · 9.8K
MEDI
1.54% · 9.4K
VAMO
0.74% · 9.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
86.08%
HOLDERS
533
TOP 12 OF 533 · RANKED BY POSITION SIZE
Blackrock, Inc.
14.0M sh · $1.14B
Vanguard Group Inc
8.8M sh · $668.69M
Blackrock Inc.
7.8M sh · $237.67M
Rtw Investments, LP
7.7M sh · $631.88M
Janus Henderson Group Plc
7.2M sh · $490M
Wellington Management Group Llp
4.9M sh · $301.86M
Armistice Capital, LLC
4.7M sh · $231.28M
State Street Corp
4.6M sh · $375.14M
Toronto Dominion Bank
4.1M sh · $314.34M
Cowen And Company, LLC
3.6M sh · $133.21M
Geode Capital Management, LLC
2.2M sh · $150.59M
D. E. Shaw & Co., Inc.
2.2M sh · $133.46M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
SCHMERTZLER MICHAEL
Sale · 6.9K shares
2026-08-26
★
DIRECTOR
SCHMERTZLER MICHAEL
Sale · 5.6K shares
2026-08-26
★
DIRECTOR
SCHMERTZLER MICHAEL
Sale · 11.9K shares
2026-08-27
★
DIRECTOR
SCHMERTZLER MICHAEL
Sale · 610 shares
2026-08-27

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 4
BUY 3
SECTOR PERFORM 1
SELL 1
NEUTRAL 1
10 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT Wells Fargo OVERWEIGHT Morgan Stanley OVERWEIGHT Cantor Fitzgerald OVERWEIGHT RBC Capital SECTOR PERFORM Jefferies BUY TD Cowen BUY B of A Securities BUY

SECTORS PEERS

PEERPRICE
ARWR$84.91COMPARE
KRYS$351.46COMPARE
PTGX$144.33COMPARE
CRNX$84.84COMPARE
PCVX$59.84COMPARE
TGTX$53.93COMPARE
ALKS$47.41COMPARE
RNA$13.64COMPARE